Alliance Health Group, UK

alliancehealthgroup.co.uk

Alliance Health Group has a unique approach to healthcare, we put consultants at the heart of the patient pathway. Through our partnerships with major insurers such as VitalityHealth we have worked collaboratively to achieve impressive NPS scores of 57. Alliance Health Group provide healthcare trusts for companies such as Rolls-Royce plc, Mitie and Anglian Water. Our consultants streamline the patient pathway and manage the process from day one, meaning a faster, more clinically focused and a more efficient journey for the patient, saving significant amounts by streamlining pathways to cut out unnecessary financial waste.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

news image

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More

MEDICAL

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

news image

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More

INDUSTRIAL IMPACT

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

news image

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

MEDICAL

IMMUNOTEK BIO CENTERS FIRST TO LAUNCH VEINVIEWER® TECHNOLOGY FOR PLASMA DONATIONS

ImmunoTek Bio Centers | April 27, 2022

news image

Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using...

Read More
news image

INDUSTRIAL IMPACT

EVAXION BIOTECH ANNOUNCES PUBLICATION OF CLINICAL DATA OF EVX-01 HEADING INTO PHASE 2B IN COLLABORATION WITH MERCK

Evaxion Biotech | January 27, 2022

Evaxion Biotech A/S a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvan...

Read More
news image

MEDICAL

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More
news image

INDUSTRIAL IMPACT

CALYXT ANNOUNCES PRICING OF OFFERING OF COMMON STOCK AND WARRANTS AND UPDATES BUSINESS AND RISK FACTOR DISCLOSURE

Cellectis Inc. | February 19, 2022

Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. , a majority-owned subsidiary of Cellectis S.A., announced the placement to an institutional investor in an underwritten offering of (i) 3,880,000 shares of Calyxt common stock, (ii) pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and (iii) common warrants to purchase up to 7,760,000 shares of its common stock. Read More

news image

MEDICAL

IMMUNOTEK BIO CENTERS FIRST TO LAUNCH VEINVIEWER® TECHNOLOGY FOR PLASMA DONATIONS

ImmunoTek Bio Centers | April 27, 2022

Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using...

Read More